title: Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children.
abstract: Intratumoral injections of recombinant heat shock protein (Hsp)70 were explored for feasibility in patients with brain tumors. Patients aged 4.5-14 years with untreated newly diagnosed tumors (n=12) were enrolled. After tumor resection, five injections of recombinant Hsp70 (total 2.5 mg) were administered into the resection cavity through a catheter. Before administration of Hsp70 and after the last injection, specific immune responses to the autologous tumor lysate were evaluated using the delayed-type hypersensitivity test. Further, peripheral blood was monitored to identify possible changes in lymphocyte subpopulations, cytokine levels, and the cytolytic activity of natural killer cells. The follow-up period in this trial was 12 months. Intratumoral injections of Hsp70 were well tolerated by patients. One patient had a complete clinical response documented by radiologic findings and one patient had a partial response. A positive delayed-type hypersensitivity test was observed in three patients. In peripheral blood, there was a shift from cytokines provided by Th2 cells toward cytokines of a Th1-cell-mediated response. These data corresponded to changes in lymphocyte subpopulations. Immunosuppressive T-regulatory cell levels were also reduced after injection of Hsp70, as well as production of interleukin-10. The cytolytic activity of natural killer cells was unchanged. The present study demonstrates the feasibility of intratumoral delivery of recombinant Hsp70 in patients with cancer. Further randomized clinical trials are recommended to assess the optimum dose of the chaperone, the treatment schedule, and clinical efficacy.
authors: Institute of Cytology of the Russian Academy of Sciences, Russian Federation ; AL Polenov Russian Research Scientific Institute of Neurosurgery, Russian Federation.
authors: Maxim A
authors: MA
authors: Shevtsov
authors: AL Polenov Russian Research Scientific Institute of Neurosurgery, Russian Federation.
authors: Alexander V
authors: AV
authors: Kim
authors: AL Polenov Russian Research Scientific Institute of Neurosurgery, Russian Federation.
authors: Konstantin A
authors: KA
authors: Samochernych
authors: IM Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, Russian Federation.
authors: Irina V
authors: IV
authors: Romanova
authors: Institute of Cytology of the Russian Academy of Sciences, Russian Federation.
authors: Boris A
authors: BA
authors: Margulis
authors: Institute of Cytology of the Russian Academy of Sciences, Russian Federation.
authors: Irina V
authors: IV
authors: Guzhova
authors: AL Polenov Russian Research Scientific Institute of Neurosurgery, Russian Federation.
authors: Igor V
authors: IV
authors: Yakovenko
authors: Research Institute of Highly Pure Biopreparations, St Petersburg, Russian Federation.
authors: Alexander M
authors: AM
authors: Ischenko
authors: AL Polenov Russian Research Scientific Institute of Neurosurgery, Russian Federation.
authors: William A
authors: WA
authors: Khachatryan
keywords: glioblastoma; heat shock protein 70; immunotherapy; malignant brain tumors